TJ-41 treatment reduced weight loss, COPD exacerbations, serum CRP, tumor necrosis factor-alpha (TNF-α), and IL-6 levels, improved COPD assessment test scores, and enhanced quality of life in patients with COPD21–23. The gene discussed is IL6; the disease is chronic obstructive pulmonary disease.